Oncology

Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake

October 24th 2023

By Skylar Jeremias

Article

Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.

Review: Similar Safety Profiles of Biosimilar, Reference Pegfilgrastim in Clinical Studies

October 17th 2023

By Deana Ferreri, PhD

Article

Researchers of a literature review found similar safety profiles between biosimilar pegfilgrastim and its reference product (Neulasta) across several phase 1 and phase 3 clinical trials.

EC Approves First MS Biosimilar; Coherus Receives CRL for Neulasta Onpro Competitor

September 27th 2023

By Skylar Jeremias

Article

With the European Commission's (EC) approval of Tyruko, Europe receives its first natalizumab biosimilar and first biosimilar to treat multiple sclerosis (MS), while Coherus Biosciences received a complete response letter (CRL) for its biosimilar for Neulasta Onpro.

Regulatory Updates From Around the Globe Provide Hope for Biosimilars

September 9th 2023

By Skylar Jeremias

Article

An approval in Australia and positive recommendations for 2 biosimilars in Europe bring hope for more affordable biologics around the world. However, another settlement for a US ustekinumab biosimilar showcases that some barriers remain.

Oncological Biosimilars Shown to Be as Safe as Their Reference Products

August 13th 2023

By Gillian McGovern

Article

Study finds patients with cancer feel reassured that biosimilars provide a safe, adequate, and cost-effective alternative to the pricier reference drug.

Sintilimab Plus Bevacizumab Biosimilar vs Avastin Is Cost-Effective in HCC

August 8th 2023

By Skylar Jeremias

Article

A Chinese study proved that combination therapy with sintilimab and a bevacizumab biosimilar was cost-effective enough in patients with hepatocellular carcinoma (HCC) to warrant use of the biosimilar over the reference product (Avastin) without compromising safety or efficacy.

Despite Global Increase in Amjevita Sales, US Sales Dropped 63%

August 5th 2023

By Skylar Jeremias

Article

Despite global sales for Amjevita (adalimumab-atto) growing by 29% year-over-year and the agent being the first adalimumab biosimilar on the US market, sales in the United States dropped 63% from the first quarter to the second quarter of 2023.

Abstracts Highlight Growing Comfortability With Trastuzumab Biosimilars in Breast Cancer

July 31st 2023

By Skylar Jeremias

Article

Abstracts presented at the annual meeting of the American Society of Clinical Oncology (ASCO 2023) emphasized the safety and efficacy of a trastuzumab biosimilar in treating HER2-positive breast cancer and growing utilization of trastuzumab biosimilars over time.

Reference Bevacizumab and Proposed Biosimilar Show High Similarity

July 27th 2023

By Justina Petrullo

Article

Reference bevacizumab and proposed biosimilar (BAT1706) demonstrate high similarity to each other.

Samsung Bioepis Report Proves Lower Biosimilar Prices Correlate With Greater Market Share

July 19th 2023

By Skylar Jeremias

Article

The second edition of Samsung Bioepis’ Biosimilar Market Report shows strong correlation between biosimilar usage and decreased drug prices, proving that biosimilars are delivering on the promise of savings and price erosion.